Safety of the spray-type adhesion barrier “AdSpray®”in pediatric laparoscopic surgery

The spray-type adhesion barrier “AdSpray®” can be easily used even in a small abdominal cavity. However, there have been no reports on the safety and efficacy of its application in children. We retrospectively examined the safety and efficacy of AdSpray® in pediatric laparoscopic surgery. We performed a retrospective review of all patients < 18 years old for whom AdSpray® was used in laparoscopic surgery at our institution between September 2017 and December 2021. As postoperative adverse events, intra-abdominal abscess, peritonitis and wound infection were evaluated. The morbidity of ileus during the postoperative follow-up period was also evaluated. Liver enzymes and the renal function before and after surgery were analyzed. A total of 64 children underwent laparoscopic surgery and simultaneous AdSpray® treatment. There were 48 children < 6 years old. There were no allergic symptoms or inflammatory reactions, liver dysfunction or renal dysfunction during and the stable period after surgery. Three patients with adhesive ileus who underwent laparoscopic surgery using AdSpray® did not show recurrent ileus in over three year of clinical follow-up. This study investigated the safety and efficacy of AdSpray® in pediatric laparoscopic surgery, and no adverse events associated with AdSpray® usage were confirmed.